Lupin receives US FDA approval to market generic Ancobon capsules
DSIJ Intelligence / 10 Jul 2017
Lupin’s Flucytosine Capsules USP, 250 mg and 500 mg are AB rated generic equivalent of Valeant Pharmaceuticals International Inc’s Ancobon Capsules, 250 mg and 500 mg. Ancobon capsules had US sales of USD 46.6 million.
On Monday,Lupin Limited has received final approval for its Flucytosine Capsules USP, 250 mg and 500 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Valeant Pharmaceuticals International Inc’s Ancobon Capsules, 250 mg and 500 mg.
Lupin’s Flucytosine Capsules USP, 250 mg and 500 mg are AB rated generic equivalent of Valeant Pharmaceuticals International Inc’s Ancobon Capsules, 250 mg and 500 mg. Ancobon capsules had US sales of USD 46.6 million.
Flucytosine Capsules USP, 250 mg and 500 mg are indicated for the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.